Manish Shah, MD

Manish A. Shah, MD, discusses how pembrolizumab with chemotherapy impacts immune responses in advanced esophageal cancer according to PD-L1 status.

Manish A. Shah, MD, discusses 5-year outcomes from KEYNOTE-590 of first-line pembrolizumab plus chemotherapy in patients with advanced esophageal cancer.

The panel closes their discussion by highlighting exciting developments on the horizon for the treatment of HCC.

Dr Ghassan K. Abou-Alfa explains the safety profiles of the discussed frontline therapy options for advanced HCC.

Key opinion leaders discuss the sequencing of systemic therapy options for patients with advanced HCC.

Dr Manish Shah reviews data from the HIMALAYA study on front-line systemic therapy in advanced HCC with tremelimumab plus durvalumab.

Julio Gutierrez, MD, and Ghassan K. Abou-Alfa, MD, discuss the results of the IMbrave150 study investigating atezolizumab plus bevacizumab in the first-line setting for advanced HCC.

Experts review data from IMbrave050 on the potential role of atezolizumab plus bevacizumab in the adjuvant setting for HCC.

Manish Shah, MD, details the role of locoregional therapy in HCC, and Julio Gutierrez, MD, comments on transplant as a curative option.

The panel explains the Child-Pugh scoring system and how staging and liver function impact treatment decisions for patients with HCC.

Key opinion leaders review the process of diagnosing HCC, the role of molecular testing, and associated challenges.

Experts provide an overview of hepatocellular carcinoma, including the risk factors and prognosis.

Manish A. Shah, MD, discusses the rationale for the phase 3 KEYNOTE-590 trial in ​locally advanced or metastatic esophageal carcinoma.

Manisha Shah, MD, Professor of Oncology at Ohio State University Medical Center, College of Medicine discusses cabozantinib in patients with radioiodine- refractory differentiated thyroid cancer.